GLSI Earnings — Greenwich LifeSciences, Inc. Post-ER Performance | BigEarnings
GLSI — Greenwich LifeSciences, Inc.
XNAS · Healthcare · Biotechnology
Price$17.98
Market Cap$263.8M
P/E—
52W Range$7.78 – $34.10
Next Earnings2026-08-13
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.
